Skip to main content
Premium Trial:

Request an Annual Quote

Serologicals Licenses from Myriad Suite of Cancer-Risk Proteins and Antibodies

NEW YORK, Jan. 15 (GenomeWeb News) - Serologicals' Chemicon International division has licensed certain tumor suppressor and breast cancer proteins and antibodies made by Myriad Genetics, the companies said today.


The exclusive agreement, which enables Chemicon to use the targets only for research purposes, covers the BRCA1, BRCA2, p16, p15, and p14 proteins and antibodies. However, the agreement "excludes commercial therapeutic and diagnostic rights and rights to fields of use that Chemicon does not currently serve," the companies said.


BRCA1 and BRCA2 are the two well-recognized cancer-susceptibility genes expressed in breast and ovarian cancers and cell lines, while cyclin-dependent kinase inhibitors p16, p15, and p14 act as tumor suppressor genes. They are known to be frequently deleted or mutated in a wide variety of human tumors.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.